A Double-Blind, Placebo-Controlled, Cross Over Study Using a Latin Square Design to Evaluate the Safety, Tolerability, and Efficacy of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjogren's Syndrome

The purpose of this study is to evaluate the effectiveness of NGX267 in the improvement of decreased salivary flow associated with primary or secondary Sjögren's syndrome.
For each patient, the study includes four periods of treatment separated by a washout period that may range from 4 - 8 days according to patient and site discretion. Each treatment period includes two overnight stays in the clinic. One dose of study drug is taken during each treatment period

Start Date01 Feb 2008

Sponsor / Collaborator

TorreyPines Therapeutics, Inc.

100 Clinical Results associated with NGX-267

100 Translational Medicine associated with NGX-267

100 Patents (Medical) associated with NGX-267

Literatures (Medical) associated with NGX-267

01 Jan 2016·Neurodegenerative DiseasesQ4 · MEDICINE

AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease

Q4 · MEDICINE

Article

Author: Eitan Gershonov ; Rodrigo Medeiros ; Niva Natan ; Hanoch Elkon ; Ilya Bezprozvanny ; Frank M. LaFerla ; Victoria Nahum ; Abraham Fisher ; Rachel Brandeis ; Lili Wu ; Nira Bar-Ner ; Daniel A. Ryskamp

We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers. We now report on a novel compound, AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concentrations of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB). AF710B (1-30 µg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment). These effects of AF710B involve σ1 receptor activation. In agreement with its antiamnesic properties, AF710B (at 30 n<smlcap>M</smlcap>), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 µ<smlcap>M</smlcap>) was less potent in PS1-KI and ineffective in APP-KI models, respectively. In female 3xTg-AD mice, AF710B (10 µg/kg, i.p./daily/2 months) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3β activity, p25/CDK5, neuroinflammation, soluble and insoluble Aβ<sub>40</sub>, Aβ<sub>42</sub>, plaques and tau pathologies. AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists. These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.

01 Mar 2009·European Journal of PharmacologyQ3 · MEDICINE

Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists

Q3 · MEDICINE

Article

Author: Pausch, Mark H. ; Uveges, Albert J. ; Tseng, Eugene ; Butera, John A. ; Popiolek, Mike ; Kramer, Angela ; Kowal, Dianne ; Carrick, Tikva ; Lock, Tim ; Heinrich, Julia N. ; Marquis, Karen L. ; Mayer, Scott C. ; Sun, Shaiu-Ching

In functional assay assessments using the five muscarinic receptor subtypes, a second generation of muscarinic M(1)-preferring receptor agonists [AC-42 (1), AC-260584 (2), 77-LH-28-1 (3) and LY-593039 (4)] was shown to have higher selectivity for muscarinic M(1) over M(3) receptor as compared to historical agonists [talsaclidine (8), sabcomeline (10), xanomeline (11), WAY-132983 (12), cevimeline (9) and NGX-267 (6)]. Another striking difference of these more recent compounds is their affinities for the dopamine D(2) and 5-HT(2B) receptors. Taken together, these results suggest that the newer compounds may have a greater clinical safety profile, especially with regard to muscarinic M(3) receptor-mediated events, than the historical agonists, but their affinities for other receptors may still compromise their use to validate the therapeutic potential of muscarinic M(1) receptor agonists.

25 Feb 2009·Journal of Biopharmaceutical StatisticsQ4 · MEDICINE

An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations

Q4 · MEDICINE

Article

Author: Murphy, Michael ; Ivanova, Anastasia

The primary objective of the dose-escalation trial for NGX267 was to estimate the maximally tolerated dose (MTD) and to gather detailed clinical and pharmacokinetic observations near the MTD. The MTD was defined based on the weighted average of moderate and severe adverse events. An adaptive design was employed to concentrate dosage assignments at or near the MTD. Favoring the acquisition of data near the MTD, at the expense of information at lower dosage levels, resulted in a shorter trial and no loss of the type of information required to inform subsequent studies where larger normal volunteer or patient samples are evaluated.

100 Deals associated with NGX-267

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05152

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sjogren's Syndrome	Phase 2	US	TorreyPines Therapeutics, Inc.	01 Feb 2008
syndrome; salt-losing, adrenogenital syndrome	Phase 2	US	TorreyPines Therapeutics, Inc.	01 Feb 2008
Alzheimer Disease	Phase 2	-	Raptor Pharmaceutical, Inc.	-
Cognition Disorders	Phase 2	-	Raptor Pharmaceutical, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis